IP Library › Granted Patent US 11,193,931
Granted Patent B2
US 11,193,931 · App. 16/335,358 · Granted Dec 7, 2021

Cellular vamp cleavage assay

Inventors: Bryony Gray (Wrexham, GB); Verity Cadd (Wrexham, GB); Matthew Beard (Wrexham, GB)
Assignee: IPSEN BIOPHARM LIMITED
G01N33/56911C07K14/33C07K14/47C07K16/1282C07K16/18C12Q1/37C07K2317/30C07K2317/92C07K2319/00G01N2333/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,193,931
App. No.
16/335,358
Filed
Mar 21, 2019
Granted
Dec 7, 2021
Kind
B2
Art Unit
1645
USPC
435/7.32
Abstract

A VAMP epitope suitable for generating an antibody against a VAMP C-terminal neurotoxin cleavage product. Method of using such an epitope to generate an antibody against cleaved VAMP. Method of using such an antibody to assay for cleavage of a VAMP by clostridial neurotoxin.

Claims (23)

1. An antigenic polypeptide consisting of 16 to 65 amino acid residues, the polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 22-3o and 48-78, wherein the antigenic polypeptide shares no more than 15 consecutive amino acid residues in common with a naturally-occurring VAMP amino acid sequence.

2. The antigenic polypeptide of claim 1 , wherein the polypeptide consists of 16 or 17 amino acid residues.

3. An antigenic protein comprising a polypeptide covalently linked to a carrier, wherein the polypeptide:

consists of 16 to 65 amino acid residues;

comprises a VAMP epitope comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEO ID NOs: 15-34 and 48-78; and shares no more than 15 consecutive amino acid residues in common with a naturally-occurring VAMP amino acid sequence.

4. A method of generating an antibody against a C-terminal VAMP cleavage product, the method comprising using a polypeptide that:

consists of 16 to 65 amino acid residues;

comprises a VAMP epitope comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 15-34 and 48-78; and shares no more than 15 consecutive amino acid residues in common with a naturally-occurring VAMP amino acid sequence;

the method comprising immunizing an animal or an egg with the polypeptide; or

the method comprising immunizing a lymphocyte in vitro with the polypeptide.

5. An antigenic protein comprising an antigenic polypeptide covalently linked to a carrier, the antigenic polypeptide consisting of 10 to 3o amino acid residues and comprising a VAMP epitope comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 1S-24 and 48-78.

6. The polypeptide of claim 1 , comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 53-78.

7. The polypeptide of claim 1 , comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 62, 66, and 75.

8. The antigenic protein of claim 3 , wherein the VAMP is VAMP 1 , VAMP 2 , VAMP 3 , VAMP 4 , VAMP 5 or YKT6.

9. The antigenic protein of claim 3 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 15, 22, 27, 32, 49, and 53.

10. The antigenic protein of claim 3 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 22-30 and 48-78.

11. The antigenic protein of claim 3 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 53-78.

12. The antigenic protein of claim 3 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 62, 66, and 75.

13. The method of claim 4 , wherein the VAMP is VAMP 1 , VAMP 2 , VAMP 3 , VAMP 4 , VAMP 5 or YKT6.

14. The method of claim 4 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 15, 22, 27, 32, 49, and 53.

15. The method of claim 4 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 22-30 and 48-78.

16. The method of claim 4 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 53-78.

17. The method of claim 4 , wherein the VAMP epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOs: 62, 66, and 75.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2021
From: GRAY, BRYONY; CADD, VERITY; FOSTER, KEITH
To: IPSEN BIOPHARM LIMITED
Reel/Frame 058490/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2019
From: GRAY, BRYONY; CADD, VERITY; BEARD, MATTHEW
To: IPSEN BIOPHARM LIMITED
Reel/Frame 048881/0144 →
Priority Claims (1)
EP 16194390 · Oct 18, 2016 · regional
Continuity (1)
Related Publication 20190219575A1 · Jul 18, 2019